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Abstract
Background: Polypharmacy is a frequent condition, but its prevalence and determinants in the Swiss mid-aged
population are unknown. We aimed to evaluate the prevalence and determinants of polypharmacy in a large Swiss
mid-aged population-based sample.
Methods: Data from 4938 participants of the CoLaus study (53% women, age range 40–81 years) were collected
between 2009 and 2012. Polypharmacy was defined by the regular use of five or more drugs.
Results: Polypharmacy was reported by 580 participants [11.8%, 95% confidence interval (10.9; 12.6)]. Participants
on polypharmacy were significantly older (mean ± standard deviation: 66.0 ± 9.1 vs. 56.6 ± 10.1 years), more
frequently obese (35.9% vs. 14.7%), of lower education (66.6% vs. 50.7%) and former smokers (46.7% vs. 36.4%) than
participants not on polypharmacy. These findings were confirmed by multivariate analysis: odds ratio and (95%
confidence interval) for age groups 50–64 and 65–81 relative to 40–49 years: 2.90 (2.04; 4.12) and 10.3 (7.26; 14.5),
respectively, p for trend < 0.001; for low relative to high education: 1.56 (1.17; 2.07); for overweight and obese
relative to normal weight participants: 2.09 (1.65; 2.66) and 4.38 (3.39; 5.66), respectively, p for trend < 0.001; for
former and current relative to never smokers: 1.42 (1.14, 1.75) and 1.63 (1.25, 2.12), respectively, p for trend < 0.001.
Conclusion: One out of nine participants of our sample is on polypharmacy. Increasing age, body mass index,
smoking and lower education independently increase the likelihood of being on polypharmacy.
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Background
In industrialized countries, population ageing is paral-
leled by an increase in the number of drugs prescribed
[1, 2]. An increasing number of subjects are with poly-
pharmacy, defined as the regular intake of five or more
medicines [1–3]. The prevalence of polypharmacy is be-
lieved to have doubled during the last decade [2, 3]. Still,
the reported prevalence rates vary considerably, from
10% in a study conducted in 2006 in the Greek general
population [4] to 75% in a study conducted in 2012 in
the Austrian nurse care system [5].
Several factors have been shown to be associated with
polypharmacy. Ageing and its associated multi-
morbidities are the most important [6–9]. The prevalence
of polypharmacy can be as high as 60% in the general
population aged over 65 years [10, 11], although high
prevalence rates have also been reported for younger
people [2, 3, 12, 13]. Indeed, two thirds of all individuals
with polypharmacy are under 70 years old [14]. Current
and/or former smoking and obesity have also been posi-
tively associated with polypharmacy [4, 15], while the ef-
fect of education is controversial, as higher levels of
polypharmacy have been reported among high [4] or low
[6, 16] educational groups, while even other studies found
no differences between educational groups [17].
Polypharmacy increases the probability of drug-drug in-
teractions and adverse drug reactions [3] and is associated
with a higher risk of falls, hospitalisation, poor functional
status, morbidity and mortality [18–20]. Nevertheless,
polypharmacy might be necessary and beneficial to the* Correspondence: Julien.Castioni@chuv.ch
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patient if adequately prescribed [21, 22], and only inappro-
priate polypharmacy should be reduced [23].
From a clinical and public health perspective, it is im-
portant to evaluate the prevalence of polypharmacy in
the mid-aged population, as it is a marker of multimor-
bidity and of potential adverse drug reactions. Further,
with the exception of a study which focused on poly-
pharmacy using health reimbursement claims [12, 24],
no information is available regarding the prevalence and
determinants of polypharmacy in the Swiss mid-aged
population.
Our study aimed to: 1) assess the prevalence of poly-
pharmacy in the Swiss mid-aged population; and 2)
identify the individual and socio-economic factors asso-
ciated with polypharmacy. We also assessed the type of
drugs most commonly prescribed to patients with
polypharmacy.
Methods
Study population and design
The Colaus study (www.colaus.ch) is an ongoing pro-
spective survey investigating the biological and genetic
determinants of cardiovascular disease in the population
of Lausanne, Switzerland. Detailed descriptions of the
study design have been reported elsewhere [25]. A sim-
ple, non-stratified random sample of 19,830 subjects
(corresponding to 35% of the source population) was
drawn [25]. Inclusion criteria were: (a) written informed
consent and (b) willingness to take part in the examin-
ation and to provide blood samples.
The baseline study was conducted between 2003 and
2006 and included 6733 participants, with a participation
rate of 41%; the first follow-up was conducted between
April 2009 and September 2012, five and a half year on
average after the baseline and included 5064 participants
(75.2%) [26].
The baseline evaluation included an interview, a phys-
ical exam, blood sampling and a set of questionnaires.
All participants were interviewed by trained recruiters
regarding personal and family history of cardiovascular
disease and risk factors and medicines taken. The ques-
tionnaires can be obtained from the authors upon re-
quest. The same procedure (questionnaires, interview
and physical examination) was applied at follow-up. The
data from the first follow-up was used in this study.
Ethical statement
This study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all proce-
dures involving human subjects were approved by the
Institutional Ethics Committee of the University of
Lausanne (decision reference 33/09). Written informed
consent was obtained from all participants.
Clinical and biological parameters
CVD and medication status were assessed by question-
naire. Smoking status was defined as never, former (irre-
spective of the time since quitting) and current
(irrespective of the amount smoked). Educational level
was categorized as low (obligatory school or apprentice-
ship), medium (high school), or high (university degree).
Marital status was dichotomized into living alone (single,
divorced, widowed) and living with somebody (married
or partnership). Country of birth was categorized into
Switzerland and other [25]. Body weight and height were
measured with participants standing without shoes in
light indoor clothes. Body weight was measured in kilo-
grams to the nearest 100 g using a Seca® scale, which
was calibrated regularly. Height was measured to the
nearest 5 mm using a Seca® height gauge [25]. Body
mass index (BMI) was defined as weight/height2. Over-
weight was defined as 25 ≤ BMI < 30 kg/m2 and obesity
as BMI ≥ 30 kg/m2. Venous blood samples (50 ml) were
drawn after an over-night fast, and most clinical chemis-
try assays were performed by the CHUV Clinical
Laboratory on fresh blood samples. Measurements in-
cluded blood lipids, liver markers, cytokines and
adipokines.
Polypharmacy
Participants were asked to bring all their medicines,
which were checked by the research assistants. Partici-
pants were asked if the medicines were prescribed by a
doctor or obtained over the counter. The regular con-
sumption of the medicines over the last six months was
also queried. Posology was not taken into account, i.e. a
patient with propranolol 3 × 40 mg a day was considered
as taking a single drug.
Polypharmacy was defined as the regular use of five or
more different pharmacologically active medicines, re-
gardless if a medicine contained one or more compo-
nents [21, 27]. Excessive polypharmacy was defined as
the regular use of ten or more medicines [6]. Regular
use was defined as a medicine taken regularly over the
past six months. Only medicines considered as medically
needed (i.e. prescribed by a doctor) were considered;
hence, we excluded medicines obtained over the counter,
alternative therapies such as plant extracts, dietary sup-
plements and homeopathy.
Exclusion criteria
Participants were excluded if they missed any informa-
tion regarding individual, clinical or socio-economic
data.
Statistical analysis
Statistical analyses were performed using Stata version
14.1 (Stata Corp, College Station, Texas, USA). Descriptive
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results were expressed as mean ± standard deviation (SD)
for continuous variables or as number of participants (per-
centage) for categorical variables. For prevalences, exact
95% confidence intervals were also computed. Bivariate
analysis was performed using Student’s t-test for continu-
ous variables and chi-square test for categorical variables.
Multivariate analysis was performed using logistic regres-
sion and results were expressed as multivariate-adjusted
odds ratio (OR) and [95% confidence interval (CI)]. Statis-
tical significance was considered for a two-sided test with
p < 0.05. Two sensitivity analyses were performed: the first
one included over the counter (OTC) drugs, and the sec-
ond considered all active substances among prescribed
and OTC drugs. As some drugs combine several pharma-
cologically different active substances, we identified the
ATC codes corresponding to combinations of different ac-
tive substances (Additional file 1: Table S1), excluding
combinations of vitamins and minerals (ATC codes A11A;
A11C; A11D; A11E; A11G¸ A11J; A12AX; B03AD and
B03AE). Categories were defined similarly to polyphar-
macy, i.e. 0–4, ≥5 and ≥10 active substances.
Results
Selection procedure and characteristics of participants
Of the 5064 participants at follow-up, 126 (2.5%) were ex-
cluded due to missing data for socio-economic characteris-
tics or body mass index, leaving 4938 participants (97.5%)
for the current analysis. The characteristics of the in-
cluded and excluded participants are summarized in
Additional file 1: Table S2. Excluded participants lived
more frequently alone, while no differences were
found for the other individual and socio-economic
characteristics.
Prevalence of polypharmacy
Prevalence of any drug use, polypharmacy and excessive
polypharmacy are summarized in Table 1. Almost six
out of ten (59.7%) participants reported taking at least
one drug; one out of nine (11.8%) was with polyphar-
macy, and slightly over 1 % (1.4%) was on excessive
polypharmacy (Table 1). Cardiovascular drugs were the
most frequent, being prescribed to over one third
(37.3%) of the participants; psychiatric drugs ranked sec-
ond highest, being prescribed to one sixth (15.8%) of the
participants. Among cardiovascular drugs, the two most
frequently prescribed categories were antihypertensive
and hypolipidemic drugs (Table 1).
Determinants of polypharmacy
The distribution of the number of drugs consumed ac-
cording to age groups is indicated in Fig. 1; the older the
participant, the more drugs he/she consumed, with a
considerable increase in the prevalence of polypharmacy.
The bivariate and multivariate analyses of the individ-
ual and socioeconomic determinants of polypharmacy
are summarized in Table 2. Participants with polyphar-
macy were older, had a higher BMI, were less well edu-
cated, and were more frequently former smokers. These
findings were further confirmed by multivariate analysis
including all determinants simultaneously (Table 2).
Conversely, no association was found between polyphar-
macy and gender, marital status or country of birth
(Table 2). Similar findings were obtained for participants
reporting excessive polypharmacy, although the associ-
ation with smoking was no longer significant (Additional
file 1: Table S3).
Sensitivity analysis
When OTC drugs were considered, the prevalence rates
of polypharmacy and excessive polypharmacy were
14.7% and 1.8%, respectively. The results of the multi-
variate analysis are provided in Additional file 1: Table S4
and Additional file 1: Table S5. Similar associations were
found as for the original analysis; further, men had a
lower likelihood of being on polypharmacy (Additional
file 1: Table S4), while no gender differences were found
for excessive polypharmacy (Additional file 1: Table S5).
When all active substances were considered (including
active substances in OTC drugs), the prevalence rate of
taking ≥5 active substances/day was 16.9% and of taking
≥10 active substances/day was 2.3%. The results of the
multivariate analysis using active substances are pro-
vided in Additional file 1: Table S6 and Additional file 1:
Table S7. Results were similar to the previous sensitivity
analysis; further, living in a couple was associated with a
lower likelihood of taking ≥10 active substances/day
(Additional file 1: Table S7).
Discussion
There are few studies on the prevalence and the deter-
minants of polypharmacy and excessive polypharmacy in
the Swiss mid-aged population [12, 28]. Our results
show that one out of nine (11.8%) participants aged be-
tween 40 and 81 is on polypharmacy, but that less than
two out of one hundred (1.4%) are on excessive poly-
pharmacy. Increasing age, body mass index, and lower
education independently increase the likelihood of being
with polypharmacy or on excessive polypharmacy; a
positive association between smoking and polypharmacy
was also found.
Prevalence of polypharmacy
The overall prevalence of polypharmacy was 11.8%, and
it increased considerably with age, from 2.9% for age
group 40–49 to 25.5% for age group 65–81. Comparison
with the literature is difficult as there are differences on
how data were collected, in the age groups and,
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definitions of polypharmacy [29]. In Switzerland, a study
based on claims from the largest health insurance re-
ported a prevalence of polypharmacy of 16.7% among
adults, and of 41.2% in individuals aged ≥65 years [12].
The prevalence was based on health claims, and only
subjects who asked for reimbursement of at least one
drug were included. The other Swiss study was based on
patients followed in a university primary care setting and
reported prevalence rates ranging between 20.8% for age
group 50–54 and 54.6% for age group 75–80 [28]. A
Scottish study based on electronic data from pharmacy
claims reported an overall prevalence of polypharmacy
of 22.1% in individuals aged ≥20 years [3], while an Irish
study using the same methodology reported a prevalence
of 21.5% in individuals aged ≥20 years; 30.2% for age
group [45–64] and 60.4% in individuals aged ≥65 years
[11]. A possible explanation for these higher values is
that individuals consuming “occasional” drugs such as
antibiotics or anti-histaminics were also included. Simi-
larly, in another Scottish study, the prevalence of
Table 1 Prevalence of polypharmacy and of the main drugs prescribed, Colaus study, Switzerland, 2009–2012, 4938 participants
Frequency n (%) 95% CI
Any drug 2947 (59.7) (58.3–61.1)
Polypharmacy (≥5 drugs) 580 (11.8) (10.9–12.7)
Excessive polypharmacy (≥10 drugs) 69 (1.4) (1.1–1.8)
Cardiovascular 1843 (37.3) (36.0–38.7)
Antihypertensive drugs 1327 (26.9) (25.6–28.1)
Angiotensin receptor blockers 644 (13.0) (12.1–14.0)
Beta-blockers 444 (9.0) (8.2–9.8)
Angiotensin converting enzyme inhibitors 350 (7.1) (6.4–7.8)
Calcium channel blockers 229 (4.6) (4.1–5.3)
Diuretics 158 (3.2) (2.7–3.7)
Other 81 (1.6) (1.3–2.0)
Hypolipidemic drugs 1029 (20.8) (19.7–22.0)
Statins 861 (17.4) (16.4–18.5)
Other hypolipidemic drugs 219 (4.4) (3.9–5.0)
Antiplatelet drugs 572 (11.6) (10.7–12.5)
Aspirin 527 (10.7) (9.8–11.6)
Vitamin K antagonists 108 (2.2) (1.8–2.6)
Psychiatric 781 (15.8) (14.8–16.9)
Antidepressants 516 (10.5) (9.6–11.3)
Anxiolytics 243 (4.9) (4.3–5.6)
Hypnotics and sedatives 230 (4.7) (4.1–5.3)
Antipsychotics 54 (1.1) (0.8–1.4)
Analgesics 657 (13.3) (12.4–14.3)
Anilides 110 (2.2) (1.8–2.7)
Non-steroidal anti-inflammatory drugs 447 (9.1) (8.3–9.9)
Opioids 61 (1.2) (0.9–1.6)
Vitamins and minerals 616 (12.5) (11.6–13.4)
Gastro-intestinal Drugs 469 (9.5) (8.7–10.3)
Antiacids 351 (7.1) (6.4–7.9)
Drugs for constipation 68 (1.4) (1.1–1.7)
Othera 114 (2.3) (1.9–2.8)
Antidiabetic drugs 274 (5.6) (4.9–6.2)
Oral antidiabetics 252 (5.1) (4.5–5.8)
Insulin 59 (1.2) (0.9–1.5)
aATC codes A01, A03, A04, A05, A07 and A09. Results are expressed as number of participants (percentage) and as 95% confidence interval (CI)
Castioni et al. BMC Health Services Research  (2017) 17:840 Page 4 of 9
polypharmacy was 36% for age group [60–70]; this
higher prevalence could be due to a different definition
of polypharmacy, i.e. ≥4 instead of ≥5 drugs [13]. Over-
all, our results indicate that prevalence of polypharmacy
is common in the Swiss mid-aged population, and that
almost one quarter of individuals aged 65–81 years are
with polypharmacy.
Determinants of polypharmacy
Increased age was associated with increased polypharmacy
and excessive polypharmacy, a finding consistently re-
ported in the literature [1, 2, 11–13]. This reflects the in-
crease in the number of pathologies requiring therapy
with ageing, or the difficulty to stop treatment once it has
been initiated, leading to cumulative prescriptions. Still,
the fact that four out of ten participants aged 65–81 were
with polypharmacy stresses the need for the optimization
of the prescriptions, such as using for example of the
START/STOPP criteria [30], the adoption of a patient-
centered rather than a disease-centered approach, and an
effective physician-patient communication [31].
Increased body mass index was associated with in-
creased polypharmacy and excessive polypharmacy rates,
a finding also in agreement with the literature [4, 32]. A
likely explanation is the wide array of comorbidities as-
sociated with obesity, namely diabetes, hypertension,
dyslipidemia and arthrosis, which frequently require
multiple treatments [33].
Participants with a lower education level presented
higher rates of polypharmacy. Such association has
already been reported, but mostly among elderly subjects
[6, 10, 16]. An explanation is that subjects with a lower
education level tend to present higher multimorbidity
rates [8, 9], possibly due to adverse socio-economic con-
ditions or to less interest for preventive measures. Still,
our results suggest that even among middle aged sub-
jects, a low educational level leads to increased rates of
polypharmacy.
Smoking was associated with a higher prevalence of
polypharmacy, a finding in accordance with another
study [4]. Possible explanations include the higher preva-
lence of pulmonary, cancer and psychiatric disease
among smokers, leading to the use of more drugs. Un-
fortunately, due the scope of the CoLaus study, detailed
information regarding those diseases is not available and
it would be of interest that this analysis be replicated.
Classes of drugs
Cardiovascular drugs were the most prescribed thera-
peutic class, a finding in agreement with the literature
[2, 11, 34]. Antihypertensives ranked first, closely
followed by statins. Possible explanations include the
relatively high prevalence of cardiovascular risk factors
in this population [35, 36] and the existence of guide-
lines regarding cardiovascular risk factor management
[37–39]. Conversely, the high prevalence of psychiatric
drugs (namely anxiolytics, hypnotics and sedatives) and
of analgesics raises some concerns, as these drugs are
not supposed to be prescribed on a long term basis.
Sensitivity analysis
Considering only the number of drugs prescribed might
underestimate the prevalence of polypharmacy, as sub-
jects can acquire other products over the counter. Con-
sidering also non-prescribed drugs increased the
prevalence of polypharmacy from 11.8% to 14.7%, but
had no effect on its determinants.
Further, as drugs might contain combinations of active
substances, simply counting the number of drugs (in-
cluding OTC) might still underestimate the prevalence
Fig. 1 Frequency of drug intake according to age group, in the 4938 participants of the CoLaus study, Switzerland
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rate of polypharmacy. Indeed, when all active substances
were considered, the prevalence of participants taking ≥5
active substances was 5.1% higher than the rate based on
drugs (0.9% higher if at least 10 active substances). Again,
no significant changes were found regarding the main de-
terminants of taking ≥5 active substances. Overall, our re-
sults suggest that the definition of polypharmacy (only
prescribed drugs, prescribed +OTC or active substances)
considerably impacts the prevalence rates but does not in-
fluence significantly its determinants. Studies assessing
both polypharmacy and active substances in the general
population are scarce and it would be of interest that our
results be replicated in other settings.
Clinical implications
With the ageing of the population, the number of indi-
viduals with polypharmacy will increase. This will
require general practitioners, hospital medical staff and
pharmacists to be increasingly attentive to such a condi-
tion, in order to prevent over-prescription and the oc-
currence of drug-drug interactions and adverse drug
reactions. In the forthcoming years, drug prescriptors
and dispensers will be required to optimize prescrip-
tions, a difficult task where the pros of adding an extra
drug and the cons related to its possible adverse effects
will have to be carefully balanced. Hence, it would be of
interest that strategies aimed at optimizing polyphar-
macy are provided to health professionals either at the
pre or at the postgraduate level. For instance, in
Switzerland, there are initiatives aimed at reducing in-
appropriate polypharmacy that provide medication rec-
onciliation to ambulatory patients [40]. Indeed, such
strategies have been shown to reduce polypharmacy and
its potential drug-drug interactions [41] and to be cost-
Table 2 Bivariate and multivariate analysis of the factors associated with polypharmacy (≥5 different drugs/day), Colaus study,
Switzerland, 2009–2012, 4938 participants
No (n = 4358) Yes (n = 580) P-value Multivariate P-value for trend
Gender 0.973
Woman 2325 (53.4) 309 (53.3) 1 (ref.)
Man 2033 (46.7) 271 (46.7) 0.92 (0.75–1.12)
Age (years) 56.6 ± 10.1 66.0 ± 9.1 <0.001
Age group (%) <0.001 <0.001
40–49 1359 (31.2) 40 (6.9) 1 (ref.)
50–64 1970 (45.2) 187 (32.2) 2.90 (2.04–4.12)
65–81 1029 (23.6) 353 (60.9) 10.3 (7.26–14.5)
BMI categories (%) <0.001 <0.001
Normal + underweight 2034 (46.7) 125 (21.6) 1 (ref.)
Overweight 1685 (38.7) 247 (42.6) 2.09 (1.65–2.66)
Obese 639 (14.7) 208 (35.9) 4.38 (3.39–5.66)
Education (%) <0.001 0.002
High 995 (22.8) 70 (12.1) 1 (ref.)
Middle 1154 (26.5) 124 (21.4) 1.15 (0.83–1.58)
Low 2209 (50.7) 386 (66.6) 1.56 (1.17–2.07)
Marital status (%) 0.121
Living alone 1851 (42.5) 266 (45.9) 1 (ref.)
Living in a couple 2507 (57.5) 314 (54.1) 0.86 (0.71–1.05)
Born in Switzerland (%) 0.303
No 1621 (37.2) 203 (35.0) 1 (ref.)
Yes 2737 (62.8) 377 (65.0) 0.87 (0.72–1.06)
Smoking status (%) <0.001 <0.001
Never 1816 (41.7) 192 (33.1) 1 (ref.)
Former 1588 (36.4) 271 (46.7) 1.42 (1.14–1.75)
Current 954 (21.9) 117 (20.2) 1.63 (1.25–2.12)
BMI Body mass index. Bivariate analysis using chi-square for categorical variables and student’s t-test for continuous variables; results are expressed as number of
participants (column percentage) or as mean ± standard deviation. Multivariate analysis using logistic regression; results are expressed as odds ratio and (95%
confidence interval)
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saving [42]. Similarly, the use of medicines combining
several drugs may tackle the treatment burden and im-
prove adherence [43].
Strengths and limitations
This study has several strengths. Firstly, it was based on
a large mid-aged population-based sample, allowing to
estimate the prevalence of polypharmacy at the popula-
tion level including non-prescribed (OTC) medicines, a
condition that studies based on pharmacy claims cannot
perform in Switzerland [3, 12]. Secondly, it clearly
assessed drugs taken on a regular basis, precluding a
possible overestimation bias due to the occasional con-
sumption of drugs. Finally, and contrary to most studies
[1–3, 6, 10–12], several definitions for polypharmacy
were applied, allowing a wider comparison with the
existing literature [22].
This study has also some limitations. First, participation
rate was low (41%), but in line with other epidemiological
studies [44]. Thus, a recruitment bias cannot be excluded,
the healthiest participants being selected, which would
underestimate the prevalence rates of polypharmacy and
excessive polypharmacy. Still, the distribution of age
groups in our sample was comparable to the source popu-
lation and there was no difference in gender distribution
between the source population and the CoLaus partici-
pants (not shown). Further, our results provide a conser-
vative estimate for the prevalence rates of polypharmacy
and excessive polypharmacy, and the fact that 25.6% of
participants aged 65–81 were with polypharmacy (and
2.7% on excessive polypharmacy) is already concerning.
Secondly, it was not possible to assess all comorbidities in
our participants; hence, it was not possible to assess if (ex-
cessive) polypharmacy was due to increased number of
comorbidities. Third, due to legal constraints, it was not
possible to cross-check the information provided by the
participants with data from medical or pharmaceutical
electronic records. No specific training regarding drug col-
lection was provided to the research assistants. Complete
medication reconciliation or tools such as the Swiss poly-
medication check or the brown bags’ method are difficult
to apply in large samples due to economic and human re-
sources issues [40, 45, 46]. However, recent studies suggest
that self-reported information on medication use closely
relates with pharmacy records [47]; hence, memory bias
might be small and the impact on prevalence rates might
be reduced.
Conclusion
In a Swiss mid-aged population-based sample, at least
one out of nine participants of our sample is on poly-
pharmacy. Age, body mass index, smoking and lower
education independently increase the likelihood of being
on polypharmacy.
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